Skip to content
10-Q

Quarterly Report

GALECTIN THERAPEUTICS INC GALT

0001140361-26-021495

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 65.86M sh
Shares Diluted Q1 2026 · Mar 31, 2026 65.78M sh
Shares Diluted Q1 2026 · Mar 31, 2025 63.2M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.87M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$7.69M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.11M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $17.72M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$131.96M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$127.92M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$113.98M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$104.79M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.31M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.03M
Total Liabilities Q1 2026 · Mar 31, 2026 $146M
Total Liabilities Q1 2026 · Dec 31, 2025 $145.73M
Current Assets Q1 2026 · Mar 31, 2026 $15.69M
Current Assets Q1 2026 · Dec 31, 2025 $19.44M
Total Assets Q1 2026 · Mar 31, 2026 $15.76M
Total Assets Q1 2026 · Dec 31, 2025 $19.53M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.08
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.08
Eps Basic Q1 2026 · Mar 31, 2025 −$0.15
Sga Expense Q1 2026 · Mar 31, 2026 $1.85M
Sga Expense Q1 2026 · Mar 31, 2025 $1.41M
Rd Expense Q1 2026 · Mar 31, 2026 $2.23M
Rd Expense Q1 2026 · Mar 31, 2025 $6.49M
Net Income Q1 2026 · Mar 31, 2026 −$5.05M
Net Income Q1 2026 · Mar 31, 2025 −$9.63M
Operating Income Q1 2026 · Mar 31, 2026 −$4.08M
Operating Income Q1 2026 · Mar 31, 2025 −$7.9M